BIA reacts to £42m investment into Touchlight

Reacting to the news  of Touchlight's £42m investment round, Steve Bates OBE, Chief Executive of the BioIndustry Association said: “UK biotech and life sciences companies have been at the heart of understanding, supporting and leading the manufacture and scale up of COVID-19 vaccines. The investment into Touchlight will give the UK further manufacturing capability in mRNA vaccines and in the innovative field of cell and gene therapies, which will benefit UK patients enormously in the years to come.”

For more information on the investment, please follow this link